Literature DB >> 21637049

Synchronous second primary neoplasms detected by initial staging F-18 FDG PET/CT examination in patients with non-Hodgkin lymphoma.

Tomáš Papajík1, Miroslav Mysliveček, Zuzana Sedová, Eva Buriánková, Vít Procházka, Luděk Raida, Zuzana Kubová, Cestmír Neoral, David Starostka, Petr Mikula, Bohuslav Melichar, Ladislava Kučerová, Martin Tichý, Karel Indrák.   

Abstract

PURPOSE OF THE REPORT: Cases of synchronous non-Hodgkin lymphoma (NHL) and second primary carcinoma in previously untreated immunocompetent patients are relatively rare. The aim of this part of our prospective study was to a revealed 2-F-18 fluoro-2-deoxy-D-glucose (F-18 FDG) positron emission tomography (PET)-positive lesion in an extranodal organ suggestive of second primary neoplasm in newly diagnosed NHL patients.
MATERIALS AND METHODS: A total of 209 patients with NHL underwent initial staging F-18 FDG PET/computed tomography (CT). The finding was assessed by a radiologist, nuclear medicine physician, and hematologist. In 6 suspicious cases (2.9%) of second neoplasm, the decision was made to perform further investigations before lymphoma therapy.
RESULTS: Two patients were diagnosed with colorectal carcinoma, 1 with esophageal adenocarcinoma, 1 with invasive ductal breast carcinoma, 1 with medullary thyroid carcinoma, and 1 with squamous cell lung carcinoma. In 5 of the 6 patients, the second solid tumor was completely asymptomatic and revealed only by F-18 FDG PET/CT examination.
CONCLUSIONS: We conclude that in patients with NHL, appropriate imaging, clinical, and histologic analysis of organ lesions detected by F-18 FDG PET/CT will occasionally demonstrate significant synchronous neoplasms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21637049     DOI: 10.1097/RLU.0b013e318217541d

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  8 in total

1.  Follicular Lymphoma mimicking Metastatic Nodes on the F-18 FDG PET/CT and MRI for Staging of Endometrial Cancer.

Authors:  Seok-Nam Yoon
Journal:  Nucl Med Mol Imaging       Date:  2016-11-05

2.  Concurrent Tumors Revealed by an Autopsy-A Case Report and Literature Review.

Authors:  Miruna Cristian; Mădălina Boșoteanu; Mariana Așchie; Angelica Potamian; Cătălin Adrian Boșoteanu; Gabriela Izabela Bălțătescu
Journal:  Case Rep Gastrointest Med       Date:  2022-06-01

3.  Synchronous breast cancer and breast lymphoma: two case reports and literature review.

Authors:  Jia Zhong; Lijun Di; Wen Zheng
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

Review 4.  Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature.

Authors:  Maria Alevizaki; Elena Kyratzoglou; Aristoteles Bamias; Marinella Tzanela; Meletios A Dimopoulos; Katerina Saltiki
Journal:  Endocrine       Date:  2013-04-23       Impact factor: 3.633

5.  Synchronous bilateral breast carcinoma and axillary non-hodgkin lymphoma: a case report and review of the literature.

Authors:  Edward F Miles; Laura L Jacimore
Journal:  Case Rep Oncol Med       Date:  2012-09-23

6.  Familial MTC with RET exon 8 Gly533Cys mutation: origin and prevalence of second malignancy.

Authors:  Katerina Saltiki; Elli Anagnostou; George Simeakis; Sofia Kouki; Anastasia Angelopoulou; Leda Sarika; Alexandra Papathoma; Maria Alevizaki
Journal:  Endocr Connect       Date:  2017-09-26       Impact factor: 3.335

7.  Lymphoma and metastatic breast cancer presenting with palpable axillary and inguinal lymphadenopathy in a 40-year-old man with rheumatoid arthritis on anti-tumor necrosis factor α therapy: a case report.

Authors:  Gourab Datta; Dorendra Maisnam
Journal:  J Med Case Rep       Date:  2013-01-15

8.  A rare case of non-invasive ductal carcinoma of the breast coexisting with follicular lymphoma: A case report with a review of the literature.

Authors:  Mikako Tamaoki; Yoshinori Nio; Kazuhiko Tsuboi; Marika Nio; Masashi Tamaoki; Riruke Maruyama
Journal:  Oncol Lett       Date:  2014-02-14       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.